$KALV
KalVista Pharmaceuticals, Inc.

2023 Q1 Form 10-Q Financial Statement

#000095017023007020 Filed on March 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.882M $6.945M
YoY Change -0.91% 95.08%
% of Gross Profit
Research & Development $20.06M $19.74M
YoY Change 1.65% 116.97%
% of Gross Profit
Depreciation & Amortization $199.0K $149.0K
YoY Change 33.56% 6.43%
% of Gross Profit
Operating Expenses $26.95M $26.68M
YoY Change 0.98% 110.82%
Operating Profit -$26.95M -$26.68M
YoY Change 0.98% 110.82%
Interest Expense $1.329M $60.00K
YoY Change 2115.0% -86.36%
% of Operating Profit
Other Income/Expense, Net $5.642M $4.216M
YoY Change 33.82% 61.59%
Pretax Income -$21.30M -$22.47M
YoY Change -5.18% 123.55%
Income Tax
% Of Pretax Income
Net Earnings -$21.30M -$22.47M
YoY Change -5.18% 123.6%
Net Earnings / Revenue
Basic Earnings Per Share -$0.75 -$0.92
Diluted Earnings Per Share -$0.75 -$917.8K
COMMON SHARES
Basic Shares Outstanding 28.28M 24.54M
Diluted Shares Outstanding 28.28M 24.48M

Balance Sheet

Concept 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $171.7M $194.8M
YoY Change -11.86% 287.17%
Cash & Equivalents $85.05M $45.58M
Short-Term Investments $86.64M $149.2M
Other Short-Term Assets $7.767M $8.388M
YoY Change -7.4% 82.35%
Inventory
Prepaid Expenses $5.250M
Receivables
Other Receivables
Total Short-Term Assets $192.1M $214.5M
YoY Change -10.41% 243.12%
LONG-TERM ASSETS
Property, Plant & Equipment $3.037M $2.215M
YoY Change 37.11% 18.58%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $197.0K $193.0K
YoY Change 2.07% -3.5%
Total Long-Term Assets $11.34M $10.59M
YoY Change 7.06% 186.47%
TOTAL ASSETS
Total Short-Term Assets $192.1M $214.5M
Total Long-Term Assets $11.34M $10.59M
Total Assets $203.5M $225.1M
YoY Change -9.59% 239.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.698M $2.185M
YoY Change -22.29% 264.17%
Accrued Expenses $8.851M $6.450M
YoY Change 37.22% 9.32%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $11.61M $9.649M
YoY Change 20.28% 48.04%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $7.421M $7.467M
YoY Change -0.62% 578.82%
Total Long-Term Liabilities $7.421M $7.467M
YoY Change -0.62% 564.92%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.61M $9.649M
Total Long-Term Liabilities $7.421M $7.467M
Total Liabilities $19.03M $17.12M
YoY Change 11.16% 124.0%
SHAREHOLDERS EQUITY
Retained Earnings -$316.8M -$226.1M
YoY Change 40.11% 47.89%
Common Stock $504.8M $436.3M
YoY Change 15.68% 105.13%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $184.4M $207.9M
YoY Change
Total Liabilities & Shareholders Equity $203.5M $225.1M
YoY Change -9.59% 239.93%

Cashflow Statement

Concept 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$21.30M -$22.47M
YoY Change -5.18% 123.6%
Depreciation, Depletion And Amortization $199.0K $149.0K
YoY Change 33.56% 6.43%
Cash From Operating Activities -$9.289M -$14.06M
YoY Change -33.96% 85.31%
INVESTING ACTIVITIES
Capital Expenditures $15.00K -$202.0K
YoY Change -107.43% 1920.0%
Acquisitions
YoY Change
Other Investing Activities -$2.502M $13.10M
YoY Change -119.09% 88.28%
Cash From Investing Activities -$2.517M $12.90M
YoY Change -119.51% 85.64%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 57.81M 772.0K
YoY Change 7388.73% -54.59%
NET CHANGE
Cash From Operating Activities -9.289M -14.06M
Cash From Investing Activities -2.517M 12.90M
Cash From Financing Activities 57.81M 772.0K
Net Change In Cash 46.01M -391.0K
YoY Change -11866.5% -136.89%
FREE CASH FLOW
Cash From Operating Activities -$9.289M -$14.06M
Capital Expenditures $15.00K -$202.0K
Free Cash Flow -$9.304M -$13.86M
YoY Change -32.89% 82.89%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Entity Central Index Key
EntityCentralIndexKey
0001348911
dei Amendment Flag
AmendmentFlag
false
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--04-30
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-01-31
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36830
dei Entity Registrant Name
EntityRegistrantName
KALVISTA PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-0915291
dei Entity Address Address Line1
EntityAddressAddressLine1
55 Cambridge Parkway
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 901E
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02142
dei City Area Code
CityAreaCode
857
dei Local Phone Number
LocalPhoneNumber
999-0075
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
KALV
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
34169438
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
85049000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30732000
CY2023Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
86636000
CY2022Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
135470000
CY2023Q1 kalv Research And Development Tax Credits Receivable
ResearchAndDevelopmentTaxCreditsReceivable
11892000
CY2022Q2 kalv Research And Development Tax Credits Receivable
ResearchAndDevelopmentTaxCreditsReceivable
14098000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8556000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
13347000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
192133000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
193647000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3037000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2178000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8101000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7862000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
197000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
193000
CY2023Q1 us-gaap Assets
Assets
203468000
CY2022Q2 us-gaap Assets
Assets
203880000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1698000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3638000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8851000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6961000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1057000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
977000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
11606000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
11576000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7421000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7211000
CY2023Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
7421000
CY2022Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
7211000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34127762
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34127762
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24550748
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24550748
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
34000
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
25000
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
504725000
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
439104000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-316777000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-250175000
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3541000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3861000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
184441000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
185093000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
203468000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
203880000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20063000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19738000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
56325000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
50954000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6882000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6945000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22818000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18848000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
26945000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
26683000
us-gaap Operating Expenses
OperatingExpenses
79143000
us-gaap Operating Expenses
OperatingExpenses
69802000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-26945000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-26683000
us-gaap Operating Income Loss
OperatingIncomeLoss
-79143000
us-gaap Operating Income Loss
OperatingIncomeLoss
-69802000
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
732000
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
258000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1424000
us-gaap Investment Income Interest
InvestmentIncomeInterest
822000
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
597000
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-198000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-237000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-529000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4313000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4156000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
11354000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
11283000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5642000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4216000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
12541000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
11576000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-21303000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-22467000
us-gaap Net Income Loss
NetIncomeLoss
-66602000
us-gaap Net Income Loss
NetIncomeLoss
-58226000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1128000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-445000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-573000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-430000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
658000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-350000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
808000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-773000
CY2023Q1 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
1000
CY2022Q1 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-176000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-84000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-296000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1785000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-619000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
319000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-907000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19518000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23086000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-66283000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-59133000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.75
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.75
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.92
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.92
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.58
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.58
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.38
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.38
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28278453
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28278453
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24479660
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24479660
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25810369
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25810369
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24449788
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24449788
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
185093000
CY2022Q3 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
168000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2642000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-23042000
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-403000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
98000
CY2022Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-16000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
164572000
CY2022Q4 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
168000
CY2022Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2506000
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-22257000
CY2022Q4 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1297000
CY2022Q4 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
52000
CY2022Q4 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-69000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
143813000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
146000
CY2023Q1 kalv Stockissuancecosts
Stockissuancecosts
300000
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
56582000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
1085000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2333000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-21303000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1128000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
658000
CY2023Q1 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
1000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
184441000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
257193000
CY2021Q3 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
608000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2795000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-16109000
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
49000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-129000
CY2021Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-23000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
244430000
CY2021Q4 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
63000
CY2021Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2860000
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-19650000
CY2021Q4 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-33000
CY2021Q4 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-295000
CY2021Q4 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-97000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
227472000
CY2022Q1 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
773000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2777000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-22467000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-445000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-350000
CY2022Q1 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-176000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
207936000
us-gaap Profit Loss
ProfitLoss
-66602000
us-gaap Profit Loss
ProfitLoss
-58226000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
530000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
408000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7481000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8432000
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
-84000
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
-296000
kalv Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
52000
kalv Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
153000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
890000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
2081000
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
1339000
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-698000
kalv Increase Decrease In Research And Development Tax Credit Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable
-2049000
kalv Increase Decrease In Research And Development Tax Credit Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable
1477000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-4440000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3659000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1911000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
228000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1701000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-279000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-52625000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-51345000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
63757000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
84415000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
112509000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
130686000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1127000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
845000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
47625000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
45426000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
482000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1443000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
300000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
56582000
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
1085000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
58149000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1443000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1168000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-539000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
54317000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5015000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
30732000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
50592000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
85049000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
45577000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1192000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3185000
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
19000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-316800000
CY2023Q1 kalv Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
171700000
CY2023Q1 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
37571000
CY2023Q1 kalv Cash And Cash Equivalents And Marketable Securities Fair Value Disclosure
CashAndCashEquivalentsAndMarketableSecuritiesFairValueDisclosure
124207000
CY2022Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
13735000
CY2022Q2 kalv Cash And Cash Equivalents And Marketable Securities Fair Value Disclosure
CashAndCashEquivalentsAndMarketableSecuritiesFairValueDisclosure
149205000
CY2023Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
86878000
CY2023Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
92000
CY2023Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
334000
CY2023Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
86636000
CY2022Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
136599000
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2000
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1131000
CY2022Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
135470000
CY2023Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
69028000
CY2023Q1 kalv Available For Sale Securities Debt Maturities After One Through Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
13269000
CY2023Q1 kalv Available For Sale Securities Debt Maturities After Two Through Four Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughFourYearsFairValue
4339000
CY2023Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
86636000
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4117000
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4168000
CY2023Q1 kalv Accrued Research Expense Current
AccruedResearchExpenseCurrent
3322000
CY2022Q2 kalv Accrued Research Expense Current
AccruedResearchExpenseCurrent
2011000
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1119000
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
474000
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
293000
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
308000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8851000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6961000
CY2023Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
5250000
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
8404000
CY2023Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
2517000
CY2022Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
2234000
CY2023Q1 us-gaap Interest Receivable And Other Assets
InterestReceivableAndOtherAssets
584000
CY2022Q2 us-gaap Interest Receivable And Other Assets
InterestReceivableAndOtherAssets
888000
CY2023Q1 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
205000
CY2022Q2 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
1821000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8556000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
13347000
CY2023Q1 kalv Contractual Obligations Remaining Commitment Including Cancellation Provisions
ContractualObligationsRemainingCommitmentIncludingCancellationProvisions
30100000
kalv Amount Associated With Indemnification
AmountAssociatedWithIndemnification
0
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
434000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1759000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1796000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1834000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1873000
CY2023Q1 kalv Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
3420000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
11116000
CY2023Q1 kalv Lessee Operating Lease Liability Minimum Payments Interest Included In Payments
LesseeOperatingLeaseLiabilityMinimumPaymentsInterestIncludedInPayments
2638000
CY2023Q1 kalv Lessee Operating Lease Liability Present Value Of Net Minimum Payments
LesseeOperatingLeaseLiabilityPresentValueOfNetMinimumPayments
8478000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1057000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7421000
CY2022Q4 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
57700000

Files In Submission

Name View Source Status
0000950170-23-007020-index-headers.html Edgar Link pending
0000950170-23-007020-index.html Edgar Link pending
0000950170-23-007020.txt Edgar Link pending
0000950170-23-007020-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
kalv-20230131.htm Edgar Link pending
kalv-20230131.xsd Edgar Link pending
kalv-ex31_1.htm Edgar Link pending
kalv-ex31_2.htm Edgar Link pending
kalv-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
kalv-20230131_cal.xml Edgar Link unprocessable
kalv-20230131_def.xml Edgar Link unprocessable
kalv-20230131_lab.xml Edgar Link unprocessable
kalv-20230131_pre.xml Edgar Link unprocessable
kalv-20230131_htm.xml Edgar Link completed
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending